JP2017088528A - Immunological detection of varicella zoster virus - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide specific antibodies applicable to the detection of varicella zoster virus infection using immuno chromatography and to provide detection reagents and the like using the same.SOLUTION: A monoclonal antibody to varicella and zoster virus glycoprotein E and an immuno chromatography test device using the same are provided.SELECTED DRAWING: None

Description

  The present invention relates to immunological detection of varicella-zoster virus (hereinafter sometimes abbreviated as “VZV”). Specifically, the present invention relates to a monoclonal antibody useful for detection of varicella / zoster virus, a detection reagent using the same, and its use (immunochromatography test device, VZV infection test method).

  Varicella and shingles are diseases caused by VZV infection. VZV enters the airway mucosa, grows at the nasopharyngeal infiltration site and regional lymph nodes, and causes primary viremia about 5 days after infection. After proliferating in the spleen, liver, etc., it causes secondary viremia and forms chickenpox on the skin. After recovering from the primary infection, life-long immunity is usually obtained, but the virus continues to infect the whole-body sensory ganglion and sometimes reactivates, resulting in shingles (Non-Patent Document 1). The trigger for reactivation of VZV is a decrease in immune status, and many of the recurrent episodes of reactivation are shingles. VZV is reactivated in one ganglion, and as a result of the spread of the virus in a neurogenic manner, VZV-infected lesions appear in a band in line with the innervation area. This lesion is often accompanied by severe pain.

  The clinical symptoms of shingles do not always appear routinely, and are often difficult to distinguish by clinical lesions alone. There are many other diseases with blisters, such as those caused by herpes viruses. Bacterial infections such as erysipelas, rashes from tea poisons, and low-temperature burns are easily mistaken for shingles. In order to distinguish this kind of lesion and reliably diagnose this lesion and enable early treatment, a reliable, simple and rapid examination method of VZV is necessary. Antiviral drugs such as valacyclovir, acyclovir, and famciclovir show significant effects on shingles. It is very important to administer such an effective drug at an early stage for VZV infection, and an early confirmed diagnosis is eagerly desired.

  VZV detection methods include virus isolation culture, detection of specific genes using nucleic acid amplification reactions, and detection of specific antigens by ELISA. Of these, virus isolation culture requires special equipment for tissue culture, and it takes a long time to obtain test results. Detection methods using nucleic acid amplification reactions also require special equipment and reagents, and lack simplicity and speed. On the other hand, the same applies to the detection by ELISA, and it is difficult to put it to practical use.

Lungu O, et al., Proc Natl Acad Sci USA 92: 10980-10984, 1995 Thomsson E. et al., J Virol Methods. 2011 Jul; 175 (1): 53-9. Haumont M. et al., Virus Res. 1996 Feb; 40 (2): 199-204.

  The immunochromatography method (hereinafter referred to as “immunochromatography method”) is simple in operation, does not require a special apparatus, and can be measured in a short time (for example, 10 to 20 minutes). In other words, the detection by the immunochromatography method surpasses each of the above-mentioned methods reported so far in terms of convenience and rapidity. Accordingly, an object of the present invention is to provide a specific antibody applicable to detection of VZV infection using immunochromatography, a detection reagent using the same, and the like.

The present inventor paid attention to glycoprotein E of VZV (hereinafter referred to as “VZVgE”) (for example, see Non-Patent Documents 2 and 3) while studying to solve the above problems. There are glycoprotein H (glycoprotein H), glycoprotein L (glycoprotein L), etc. as index antigens of VZV, but VZVgE has almost no crossing with herpes simplex virus type 1 and 2 (in past reports, However, it is a major antigen that is present in large quantities. Although monoclonal antibodies against VZVgE that can be applied to Western blots, immunoprecipitation, ELISA, etc. are commercially available (for example, provided by abcam and Santa Cruz Biotec), due to problems with specificity and sensitivity, immunochromatography Is not realized. Under such circumstances, the present inventor has repeatedly studied to obtain a monoclonal antibody applicable to the immunochromatography method. As a result, we succeeded in obtaining multiple antibodies that are extremely specific and enable VZV detection by immunochromatography. In fact, when immunochromatography was performed by combining antibodies that were successfully obtained, only VZV was positive (negative for herpes simplex virus type 1 (HSV Type 1) and type 2 (HSV Type 2)).
The following invention is based on the above-mentioned results.
[1] A monoclonal antibody against varicella-zoster virus glycoprotein E, which is used for immunochromatography.
[2] The monoclonal antibody is (1) an antibody produced by a hybridoma of NITE ABP-02142, or (2) an antibody produced by a hybridoma of NITE ABP-02143. [1] The monoclonal antibody described in 1.
[3] A varicella-zoster virus detection reagent comprising the monoclonal antibody according to [1] or [2].
[4] The detection reagent according to [3], wherein the monoclonal antibody is labeled with colored synthetic polymer particles or metal colloid particles.
[5] The detection reagent according to [4], wherein the metal colloid particles are gold colloid particles.
[6] A varicella-zoster virus detection kit comprising the detection reagent according to any one of [3] to [5].
[7] A first specific antibody comprising a monoclonal antibody against varicella / zoster virus glycoprotein E, a second specific antibody comprising a monoclonal antibody against varicella / zoster virus glycoprotein E, and a membrane carrier,
The first specific antibody is immobilized on the membrane carrier to constitute a detection unit;
The immunochromatographic test device, wherein the second specific antibody is labeled with a labeling substance and is carried at a position away from the detection unit.
[8] The first specific antibody is an antibody produced by a hybridoma having an accession number: NITE ABP-02142,
The second specific antibody is an antibody produced by the hybridoma of accession number: NITE ABP-02143;
The test device according to [7].
[9] The test device according to [7] or [8], wherein the labeling substance is colored synthetic polymer particles or metal colloid particles.
[10] The test device according to [9], wherein the metal colloid particles are gold colloid particles.
[11] A varicella-zoster virus infection test method using the immunochromatography test device according to any one of [7] to [10].
[12] A labeled antibody obtained by labeling the monoclonal antibody according to [1] or [2] with metal colloid particles.
[13] The labeled antibody according to [12], wherein the metal colloid particles are gold colloid particles.
[14] A hybridoma having a reception number of NITE ABP-02142 or NITE ABP-02143.

An example of the structure of a test strip.

As shown in Examples described later, two types of monoclonal antibodies extremely useful for detection of VZV by immunochromatography were obtained by immunological techniques using VZVgE as an antigen. In other words, we succeeded in obtaining an anti-VZVgE monoclonal antibody applicable to immunochromatography. This result also shows that the anti-VZVgE monoclonal antibody is useful for detection of VZV by immunochromatography. A first aspect of the present invention is based on the results or knowledge, and provides a monoclonal antibody against VZVgE, which is used for immunochromatography. Particularly preferred monoclonal antibodies are the two monoclonal antibodies shown in the Examples described later (VZ9 and VZ22 clone numbers are given for identification). Hybridoma clones producing these antibodies are deposited with a predetermined depository as follows.
<Hybridoma clone VZ9>
Depositary institution: National Institute for Product Evaluation Technology Patent Microorganism Depositary Center (〒292-0818) Room 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 122 Date of receipt: October 21, 2015 Receipt Number: NITE ABP-02142

<Hybridoma clone VZ22>
Depositary institution: National Institute for Product Evaluation Technology Patent Microorganism Depositary Center (〒292-0818) Room 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 122 Date of receipt: October 21, 2015 Receipt Number: NITE ABP-02143

  The monoclonal antibody (anti-VZVgE antibody) of the present invention can be obtained from a hybridoma prepared according to a conventional method with reference to the information in this specification. For example, an appropriate mammal (eg, mouse, rat, etc.) is immunized with VZVgE mixed with an appropriate adjuvant as necessary. A hybridoma can be obtained by fusing antibody-producing cells such as spleen cells and B lymphocytes of the animal with myeloma cells derived from an appropriate animal (eg, mouse, rat, etc.). Cell fusion can be performed by, for example, a polyethylene glycol (PEG) method in which antibody-producing cells and myeloma cells are fused in the presence of polyethylene glycol in an appropriate medium. After cell fusion, the hybridoma is selected with a selective medium such as HAT medium (medium containing hypoxanthine, aminopterin, and thymidine), and the ability of the hybridoma to produce an antibody recognizing VZVgE is determined according to a conventional method (for example, EIA method). Perform screening. Subsequently, a hybridoma producing a desired antibody is cloned according to a conventional method (for example, limiting dilution method), and a hybridoma producing a monoclonal antibody is selected.

  The monoclonal antibody of the present invention is labeled as necessary. Labeling may be performed by a conventional method. The labeling substance used for labeling is preferably an insoluble particulate substance. Insoluble particulate materials include latex, polyethylene, polypropylene, polystyrene, styrene-butadiene copolymer, polyvinyl chloride, polyvinyl acetate, polyacrylamide, polymethacrylate, styrene-methacrylate copolymer, polyglycidyl methacrylate, acrolein-ethylene glycol. Colored synthetic polymer particles obtained by labeling synthetic polymers such as dimethacrylate copolymers with dye molecules, metal colloidal particles (gold, silver, copper, iron, platinum, palladium, mixtures thereof (for example, gold and platinum) A mixture of gold, silver, a mixture of palladium and platinum), red blood cells, and the like. Particles that allow easy and quick observation of changes visually are preferred, and colored synthetic polymer particles or metal colloid particles may be employed. The particle diameter of the particles is, for example, 15 to 100 nm, preferably 30 to 80 nm. As the metal colloidal particles, commercially available products may be used, or they may be prepared by conventional methods. Among metal colloidal particles, gold colloidal particles are preferable because they are easy to use.

  The labeling method will be described taking the case of colloidal metal particles as an example. 0.1 to 100 mg, preferably 0.5 to 20 mg of anti-VZVgE antibody is usually used per 1 liter of colloidal metal particle solution (usually about 2.0 at 540 nm). And stir refrigerated or at room temperature for 5 minutes to 24 hours. Next, blocking with bovine serum albumin (BSA) (usually 0.01 to 10 g, preferably 0.1 to 2 g) or the like, and anti-VZVgE antibody labeled with metal colloid particles can be obtained as a precipitate after centrifugation. As the buffer solution, a buffer solution usually used in immunological tests, such as Tris buffer solution, phosphate buffer solution and the like can be used. The pH of the buffer is usually in the range of 4.5 to 9.5, preferably 5.5 to 8.5.

  The monoclonal antibody of the present invention is useful as an active ingredient of a VZV detection reagent. In other words, a VZV detection reagent can be constructed using the monoclonal antibody of the present invention. The VZV detection reagent comprising the monoclonal antibody of the present invention as an active ingredient (the reagent of the present invention) is characteristic in that it can be used for immunochromatography, and is distinguished from previously reported or commercially available reagents (such as labeled anti-VZVgE antibody).

  The reagent of the present invention enables easy, rapid and highly sensitive detection of VZV infection using immunochromatography. The reagent of the present invention can also be used as an element of a detection kit. That is, the present application also provides a detection kit containing the reagent of the present invention as a main component. Other reagents (developing solvent, buffer solution, etc.) and / or devices or instruments (containers, reaction devices, etc.) used in carrying out the detection method may be included in the kit. Further, an antigen (VZVgE or a part thereof) may be included in the kit. Usually, an instruction manual is attached to the kit of the present invention.

  Using the monoclonal antibody (anti-VZVgE antibody) of the present invention, a test instrument (immunochromatography test device) for detecting VZV infection can be constructed. That is, the present invention also provides an immunochromatographic test device using a specific anti-VZVgE antibody. The test device of the present invention comprises a first specific antibody that is an anti-VZVgE antibody, and a second specific antibody that is also an anti-VZVgE antibody, and a membrane carrier. Preferably, clone VZ9 is used as the first specific antibody and clone VZ22 is used as the second specific antibody. According to this combination, VZV can be detected with extremely high specificity.

  The first specific antibody is immobilized on a membrane carrier to constitute a detection unit. On the other hand, the second specific antibody is labeled with a labeling substance and is carried at a position away from the detection unit.

  In the present specification, “fixed” means that the antibody is arranged on a carrier such as a membrane so that the antibody does not move. “Supported” means that the carrier is movably disposed in or on the surface. Hereinafter, the configuration of the test device will be described with reference to FIG. 1 (a specific example test strip). The first specific antibody is a capture antibody and is fixed to a carrier to constitute a detection unit. The “detection unit” refers to a site that captures a complex of an antigen and a second specific antibody in a specimen formed by an antigen-antibody reaction and detects the presence of the antigen.

  The carrier is made of a material that can bind a protein by a physical action such as electrostatic action or hydrophobic interaction and can develop a component in the specimen, an antigen-second specific antibody complex, and the like. Examples of the material for the membrane carrier include nitrocellulose, polyvinylidene difluoride (PVDF), and cellulose acetate. Preferably, the carrier is in the form of a membrane (membrane carrier). In addition to the detection unit, the carrier preferably includes a control unit for confirming whether or not the specimen is properly developed. A substance capable of binding to the second specific antibody is immobilized on the control part. Preferably, the detection unit and the control unit can be installed in a line on the carrier in a direction crossing the deployment direction (also referred to as “test line” and “control line”, respectively). The positional relationship between the detection part and the control part on the carrier is not limited, but usually, the control part is formed downstream of the detection part.

  The method for immobilizing the substance capable of binding to the capture antibody and the second specific antibody can be performed according to a conventional method depending on the kind of the carrier. For example, a suitably diluted antibody solution can be applied by using a commercially available antibody applicator and dried for drying. The amount of the capture antibody immobilized on the detection unit is preferably 0.05 to 10 μg, more preferably 0.1 to 3 μg.

  The second specific antibody is an antibody labeled with a labeling substance, that is, a “labeled antibody”, and is supported on a carrier such as a membrane at a position away from the detection unit. Typically, the carrier carrying the labeled antibody is a separate member from the carrier on which the capture antibody is immobilized. The labeled antibody carrying member carrying the second specific antibody (labeled antibody) is arranged on the upstream side of the detection unit. The labeled antibody carrying member carries the labeled antibody in a dry state and releases the labeled antibody when infiltrated with a liquid. Examples of the material of the labeled antibody carrying member include glass fiber, cellulose fiber, and plastic fiber. The labeled antibody-carrying member carries the labeled antibody by impregnating the labeled antibody-carrying member with an appropriate buffer containing the labeled antibody, or by adding an appropriate buffer containing the labeled antibody to the labeled antibody-carrying member and drying. Can be made. The amount of the labeled antibody carried on the labeled antibody carrying member is preferably 0.01-1 μg, more preferably 0.03-0.3 μg.

  The sample addition member is disposed on the upstream side of the labeled antibody carrying member, and preferably, at least the lower surface of the downstream region in the sample addition member is in contact with the upper surface of the upstream region in the labeled antibody carrying member. It is preferable that a part of the labeled antibody carrying member is sandwiched between the lower surface of the specimen adding member and the upper surface of the upstream region of the carrier. Preferably, an absorbent member disposed downstream of the carrier is provided. The absorbing member is arranged such that the lower surface of the upstream region is in contact with the upper surface of the region existing downstream of the detection part of the carrier.

  In the test device of the present invention, when a liquid sample pretreated as necessary is dropped onto the sample addition member, the labeled antibody support member is infiltrated, and the mixture of the sample and the labeled antibody is a carrier (typically a membrane carrier). ) And expand toward the detection part in the carrier. When VZVgE (antigen) is contained in the specimen (that is, in the case of VZV infection), the antigen and labeled antibody form an immune complex. Then, the complex is captured by the capture antibody by the antigen-antibody reaction in the detection unit, and accumulates and develops color. Therefore, it is possible to visually observe the degree of coloration in the detection unit and determine the presence or absence of the antigen in the sample. When the carrier is provided with a control part, the labeled antibody remaining without forming a complex with the antigen in the sample passes through the detection part, and is immobilized on a substance that can bind to the labeled antibody and is immobilized on the downstream control part. Captured, accumulated, and colored.

  The specimen used for the test device of the present invention is a specimen that may contain VZV. Examples of biological material that can be used as a specimen include blister contents, but are not limited thereto.

Sample pretreatment includes dissolving a biological material collected from a subject suspected of having VZV infection in a pretreatment reagent and preparing a liquid to be dropped onto a test device. Such pre-processing is performed in order to make it possible to develop the specimen, or to allow good development of the specimen. Various buffers can be used as the pretreatment reagent. As the buffer solution, a buffer solution usually used for immunological tests, for example, Tris buffer solution, phosphate buffer solution, Good buffer solution and the like can be used. A surfactant may be included in the pretreatment reagent for the purpose of reducing the non-specific binding reaction. As surfactants, Triton X-100 (trade name, polyethylene glycol mono-p-isooctylphenyl ether), Tween 20 (polyoxyethylene sorbitan monolaurate), Tween 80 (polyoxyethylene sorbitan monooleate), CHAPS (3- [(3-Colamidopropyl) dimethylammonio] propanesulfonic acid), SDS (sodium dodecyl sulfate), and the like can be used. Two or more surfactants may be used in combination.
EXAMPLES Hereinafter, although this invention is demonstrated in detail using an Example, this invention is not limited to an Example.

1. Production of monoclonal antibodies specific for VZVgE (immunization and antibody purification)
An attempt was made to obtain a specific monoclonal antibody against the antigen protein by the following method.
<Material>
(1) Antigen
VZVgE
(2) Immunized animals
BALB / cA mouse 6 weeks old female (CLEA Japan) 3 (3) Adjuvant
TiterMaxGold (G-3 Funakoshi)
(4) Mouse myeloma cells
P3U1
(5) Medium / Equipment / Reagent
RPMI-1640 medium (11875-119 GIBCO)
Sodium pyruvate solution (11360-070 GIBCO)
Penicillin-streptomycin-glutamine solution (10378-016 GIBCO)
HAT supplement (21060-017 GIBCO)
HT supplement (11067-030 GIBCO)
FBS (S1560 BWT)
PEG1500 (783641 Roche)
DMS0 (D2650 SIGMA)
96-well culture plate (92696 TPP)
24-well culture plate (92424 TPP)
Sterilization Petri dish (34153 Nipro)
Freezing tube (MS-4503 Sumitomo Bakelite)
(6) Antibody screening equipment and reagents
ELISA microplate (442404 nunc)
Anti-mouse IgG labeled antibody (1030-04 Cosmo Bio)
Monoclonal antibody isotyping kit (1493027 Roche)
(7) Mouse ascites and antibody purification
BALB / cA mouse Retired female (CLEA Japan)
Pristan (42-002 Cosmo Bio)
HiTrapProtein G (17-0404-03 GE Healthcare)

<Method>
(1) Immunization to mice
Equal amounts of VZVgE and TiterMaxGold adjusted to 6 mg / ml were mixed, and an emulsion was prepared using a glass syringe. Antigen equivalent to 100 μg was administered subcutaneously to BALB / cA mice in 2 weeks, 2 weeks later, 40 μg of VZVgE solution alone was administered subcutaneously 1 to 2 weeks later, and 3 days later, whole blood was collected under anesthesia. The spleen and various lymph nodes were collected.

(2) Culture of myeloma cells
Mouse myeloma cells (P3U1) were subcultured using RPMI1640 medium supplemented with pyruvic acid, glutamic acid and penicillin-streptomycin (RPMI medium) with FBS added to 10%. For cell fusion, a well-formed logarithmic growth phase was used.

(3) Cell fusion Each lymphoid tissue collected from the sensitized mouse was minced on # 200 mesh, lightly pressed with a glass rod equipped with a silicone stopper, and lymphocytes were filtered and collected while adding medium. Cells were washed by centrifugation at 1200 rpm for 10 minutes, and the number of cells was counted. The myeloma cells were transferred to a 50 ml conical tube, counted, and washed by centrifugation at 1000 rpm for 5 minutes. Thereafter, the cell number was adjusted so that the ratio of lymphocytes to myeloma cells was in the range of 5: 1 to 10: 1, mixed, and centrifuged (1200 rpm for 10 minutes) to obtain a cell pellet.

  For cell fusion, 1 ml of PEG solution of the cell pellet was added with slow stirring over 1 minute, and then reacted with stirring for 2 minutes. Thereafter, 1 ml of RPMI1640 solution was added over 1 minute, the same operation was performed 3 times, and 12 ml of RPMI1640 solution was added over 3 minutes. After leaving still for 10 minutes in a 37 ° C. incubator, the cells were collected by centrifugation at 1000 rpm for 5 minutes, suspended in RPMI medium containing 15% FBS supplemented with HAT supplements, and seeded on 10 96-well culture plates. At that time, mouse thymocytes were used as feeder cells.

The hybridoma was selectively grown by culturing in a CO ₂ incubator for 1 week.

(4) Antibody screening
Add 50 μl of VZVgE diluted to 1 μ / ml with PBS to a 96-well microplate for ELISA, react at room temperature for 2 hours or refrigerate overnight, and then add 100 μl of 0.5% skim milk for blocking and antigen binding A plate was used.

  One week after cell fusion, approximately 50 μl of culture supernatant was aseptically collected from each culture plate, placed in an antigen-binding plate, and allowed to react at room temperature for 1 hour. Thereafter, the plate was washed three times with physiological saline, and then an enzyme-labeled anti-mouse IgG antibody diluted 2500 times with 0.5% skim milk was reacted at room temperature for 1 hour. After washing in the same manner, color was developed with an enzyme substrate solution, and monoclonal antibody positive wells that bind to the antigen were selected.

(5) Cloning
The hybridoma selected by ELISA was cloned by the limiting dilution method. That is, a cell suspension was prepared and seeded on a 96-well culture plate previously seeded with feeder cells so that there was one hybridoma cell per well. Colonies that grew after one week were confirmed, and the same antibody screening was performed. Cloning was performed twice to confirm that the cells were completely single. As the medium, RPMI medium supplemented with 15% FBS and HT supplement was used.

(6) Clone establishment and cell freezing Hybridomas that became single cells were expanded in a petri dish from a 24-well culture plate and cryopreserved in 2-5 × 10 ⁸ cells / tube. As a freezing medium, a RPMI medium containing 15% FBS and HT supplements and DMSO added to 10% was used. The medium was wrapped in a paper towel and stored in an ultra-low temperature freezer at -85 ° C.

(7) Mouse ascites and antibody purification BALB / cA retired mice to which 0.5 ml of pristane was administered intraperitoneally more than 1 week before were inoculated with 0.5-1 × 10 ⁷ hybridoma cells, approximately 7-10 days later The accumulated ascites was obtained. Ascites was fully coagulated, solid matter was precipitated by centrifugation at 3000 rpm for 15 minutes, and the supernatant was separated. To the supernatant, sodium azide was added to 0.1% as a preservative and stored in a refrigerator until purification.

  For antibody purification from ascites, use a HiTrapProtein G column, bind PBS to the protein G column and wash with PBS, and use 0.1 M glycine HCl Buffer pH 2.8 for antibody elution after washing. 1M Tris was used for the sum. The eluted antibody was concentrated with 50% saturated ammonium sulfate, sufficiently dialyzed against PBS, added with 0.05% sodium azide and stored in the refrigerator.

  For the purity test of the purified antibody, cellulose acetate membrane electrophoresis was performed, and a single band was confirmed in the ν region.

<Result>
Cell fusion experiments were performed using 3 mice. As a result, 10 clones from the No. 1 mouse, 3 clones from the No. 2 mouse, and 10 clones from the No. 3 mouse were selected in the primary screening. The antibodies produced by these clones were purified and their performance was evaluated by immunochromatography. As a result, extremely good results were obtained with the combination of clone VZ9 (capture antibody) and clone VZ22 (labeled antibody). Hybridoma clones producing these antibodies were deposited as follows.
<Hybridoma clone VZ9>
Depositary institution: National Institute for Product Evaluation Technology Patent Microorganism Depositary Center (〒292-0818) Room 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 122 Date of receipt: October 21, 2015 Receipt Number: NITE ABP-02142

<Hybridoma clone VZ22>
Depositary institution: National Institute for Product Evaluation Technology Patent Microorganism Depositary Center (〒292-0818) Room 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 122 Date of receipt: October 21, 2015 Receipt Number: NITE ABP-02143

2. Immunochromatographic test device 2-1. Preparation of labeled antibody carrying member Based on the above results, it was decided to use the anti-VZVgE antibody produced by the hybridoma clone VZ22 as the labeled antibody. Anti-VZVgE antibody was diluted with 5 mM phosphate buffer (pH 7.4) to a concentration of 0.05 mg / ml. After adding 0.1 ml of 50 mM phosphate buffer (pH 7.4) to 0.5 ml of colloidal gold suspension (BBI: average particle size 60 nm) and mixing, add 0.1 ml of the diluted monoclonal antibody solution above to room temperature. Left for 10 minutes. To the solution after standing, 0.1 ml of 10% by weight bovine serum albumin (BSA) solution diluted with 10 mM phosphate buffer was added and stirred sufficiently, followed by centrifugation at 8,000 × g for 15 minutes. The supernatant was removed again, and a 10 mM phosphate buffer solution having a pH of 7.4 was added to the residue and well dispersed with an ultrasonic crusher to obtain a labeled antibody solution. This labeled antibody solution was uniformly added to a glass fiber pad (Millipore: GFPC203000) having a width of 16 mm and a length of 100 mm, and then dried with a vacuum dryer to obtain a labeled antibody carrying member.

2-2. Preparation of a nitrocellulose membrane carrier provided with a detection part and a control part A phosphate buffer (pH 7. 5) containing 5% by mass of isopropyl alcohol with an antibody (antibody produced by hybridoma clone VZ9) different from the labeled antibody of 2-1 above. In 4), the solution was diluted to a concentration of 1.3 mg / ml, and prepared as a detection portion fixing antibody (capture antibody) solution. One end of the antibody solution for immobilizing the detection portion 25 cm long × 2.5 cm wide nitrocellulose membrane (Millipore: HF120) on the long axis side (this end is the upstream end in the development direction, and the opposite side is the downstream end) In a linear manner with an application amount of 1 μl / cm, using an antibody applicator (manufactured by BioDot) at a position 1 cm away from. Furthermore, anti-mouse IgG antibody was applied linearly at a coating amount of 1 mg / ml at a position 1.5 cm away from the upstream end of the nitrocellulose membrane. After coating, the film was dried at 42 ° C. for 60 minutes to obtain a nitrocellulose membrane carrier having a detection part and a control part.

2-3. Production of immunochromatographic test device A plastic backing sheet was adhered to the opposite side (this surface is the lower surface) of the nitrocellulose membrane carrier of 2-2 described above (this surface is the upper surface). Next, the labeled antibody carrying member of 2-1 above is placed on the upper surface of the nitrocellulose membrane carrier so that the upstream end of the nitrocellulose membrane overlaps by 2 mm, and further a glass fiber sample having a width of 5 mm and a length of 23 mm. A pad (manufactured by Pall Co., Ltd .: 8000006801) was placed and pasted so as to overlap the upper surface of the labeled antibody carrying member by 2 mm. On the other hand, an absorbent pad (made by Pall) having a width of 5 mm and a length of 25 mm was attached to the upper surface of the nitrocellulose membrane carrier so that the downstream end of the nitrocellulose membrane carrier overlapped by 15 mm. Finally, 5 mm was cut along the long axis direction to obtain an immunochromatographic test device.

3. VZV immunochromatography Gold colloidal particles (Tanaka Kikinzoku, 60m, Lot A703) 1ml anti-VZV monoclonal antibody (antibody produced by hybridoma clone VZ22) 1ml (40μg / ml) was mixed and sensitized for 10 minutes at room temperature, then 1ml The sensitized gold colloid was suspended in PBS.

On the other hand, an anti-VZV monoclonal antibody (antibody produced by hybridoma clone VZ9) was coated on a nitrocellulose membrane (Millipore). On this film, a mixture of sensitized gold colloid and virus antigen (VZV, HSV Type 1 or Type 2) was dropped about 2 cm apart, allowed to stand for 15 minutes, and then judged. As a result, only VZV was positive as follows.
VZV: +++
HSV Type 1: −
HSV Type 2: −

  The present invention provides an anti-VZVgE monoclonal antibody applicable to immunochromatography. According to the immunochromatography method using the monoclonal antibody, simple, rapid and highly sensitive detection of VZV infection is possible.

  The present invention is not limited to the description of the embodiments and examples of the invention described above. Various modifications may be included in the present invention as long as those skilled in the art can easily conceive without departing from the description of the scope of claims. The contents of papers, published patent gazettes, patent gazettes, and the like specified in this specification are incorporated by reference in their entirety.

Claims (14)

  Monoclonal antibody against varicella-zoster virus glycoprotein E for immunochromatography.   2. The monoclonal antibody of claim 1, wherein the monoclonal antibody is (1) an antibody produced by a hybridoma of NITE ABP-02142, or (2) an antibody produced by a hybridoma of NITE ABP-02143. Monoclonal antibody.   A varicella / zoster virus detection reagent comprising the monoclonal antibody according to claim 1 or 2.   The detection reagent according to claim 3, wherein the monoclonal antibody is labeled with colored synthetic polymer particles or metal colloid particles.   The detection reagent according to claim 4, wherein the metal colloid particles are gold colloid particles.   A varicella-zoster virus detection kit comprising the detection reagent according to any one of claims 3 to 5. A first specific antibody comprising a monoclonal antibody against varicella-zoster virus glycoprotein E, a second specific antibody comprising a monoclonal antibody against varicella-zoster virus glycoprotein E, and a membrane carrier,
The first specific antibody is immobilized on the membrane carrier to constitute a detection unit;
The immunochromatographic test device, wherein the second specific antibody is labeled with a labeling substance and is carried at a position away from the detection unit. The first specific antibody is an antibody produced by the hybridoma of accession number: NITE ABP-02142;
The second specific antibody is an antibody produced by the hybridoma of accession number: NITE ABP-02143;
The test device according to claim 7.   The test device according to claim 7 or 8, wherein the labeling substance is colored synthetic polymer particles or metal colloid particles.   The test device according to claim 9, wherein the metal colloid particles are gold colloid particles.   A varicella-zoster virus infection test method using the immunochromatographic test device according to any one of claims 7 to 10.   A labeled antibody obtained by labeling the monoclonal antibody according to claim 1 or 2 with metal colloid particles.   The labeled antibody according to claim 12, wherein the metal colloid particles are gold colloid particles.   A hybridoma having a receipt number of NITE ABP-02142 or NITE ABP-02143.

Images